Catalyst Event

Gilead Sciences Inc (GILD) · Other

From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)

5/22/2026, 12:00:00 AM

OtherSentiment: Positive

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Hepcludex (bulevirtide-gmod) on 2026-05-22, the first and only approved treatment for adults with chronic hepatitis delta virus (HDV). Analysts forecast a high price impact (>=10%) as a major regulatory milestone for a first-in-class drug, expected.

Korean Translation

2026-05-22 미국 식품의약국(FDA)이 만성 D형 간염 바이러스(HDV) 성인 환자 치료를 위한 최초이자 유일한 치료제인 헵클루덱스(부레비르타이드-지모드)를 신속 승인함. 분석가들은 주요 규제 이정표로서 10% 이상의 높은 주가 영향이 있을 것으로 예상됨.

Related Recent Events

View Full Timeline